Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Oct;61(4):677.e1-14.
doi: 10.1016/j.jaad.2009.03.016.

Selection criteria for genetic assessment of patients with familial melanoma

Sancy A Leachman  1 , John Carucci, Wendy Kohlmann, Kimberly C Banks, Maryam M Asgari, Wilma Bergman, Giovanna Bianchi-Scarrà, Teresa Brentnall, Brigitte Bressac-de Paillerets, William Bruno, Clara Curiel-Lewandrowski, Femke A de Snoo, Tadeusz Debniak, Marie-France Demierre, David Elder, Alisa M Goldstein, Jane Grant-Kels, Allan C Halpern, Christian Ingvar, Richard F Kefford, Julie Lang, Rona M MacKie, Graham J Mann, Kurt Mueller, Julia Newton-Bishop, Håkan Olsson, Gloria M Petersen, Susana Puig, Darrell Rigel, Susan M Swetter, Margaret A Tucker, Emanuel Yakobson, John A Zitelli, Hensin Tsao
Affiliations
Review

Selection criteria for genetic assessment of patients with familial melanoma

Sancy A Leachman et al. J Am Acad Dermatol. 2009 Oct.

Abstract

Approximately 5% to 10% of melanoma may be hereditary in nature, and about 2% of melanoma can be specifically attributed to pathogenic germline mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A). To appropriately identify the small proportion of patients who benefit most from referral to a genetics specialist for consideration of genetic testing for CDKN2A, we have reviewed available published studies of CDKN2A mutation analysis in cohorts with invasive, cutaneous melanoma and found variability in the rate of CDKN2A mutations based on geography, ethnicity, and the type of study and eligibility criteria used. Except in regions of high melanoma incidence, such as Australia, we found higher rates of CDKN2A positivity in individuals with 3 or more primary invasive melanomas and/or families with at least one invasive melanoma and two or more other diagnoses of invasive melanoma and/or pancreatic cancer among first- or second-degree relatives on the same side of the family. The work summarized in this review should help identify individuals who are appropriate candidates for referral for genetic consultation and possible testing.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: None declared.

References

    1. Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, et al. Population-based analysis of prognostic factors and survival in familial melanoma. J Clin Oncol. 2005;23:7168–7177. - PubMed
    1. Kefford R, Bishop J, Tucker M, Bressac-de Paillerets B, Bianchi-Scarra G, Bergman W, et al. Genetic testing for melanoma. Lancet Oncol. 2002;3:653–654. - PubMed
    1. Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44:99–106. - PMC - PubMed
    1. Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66:9818–28. - PubMed
    1. Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst. 2002;94:894–903. - PubMed

Publication types